Biogen acquires Apellis Pharmaceuticals for $5.6 billion
Biogen, a company specializing in drug development, has announced its acquisition of Apellis Pharmaceuticals for <strong>$5.6 billion</strong>. This move aims to expand Biogen's capabilities in treating kidney diseases, addressing the growing need for effective therapies.